IE 11 is not supported. For an optimal experience visit our site on another browser.

Market Harmonics Issues Update to Its Independent Research Report on Renhuang Pharmaceuticals, Inc. Highlighting RHGP's Compelling Valuation in the Chinese Pharmaceutical Industry

/ Source: MarketWire announces that its client, Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP) has been featured in an Independent Research Report by Tony Carrion, founder of Market Harmonics. This update highlights RHGP's "lowest P/E multiple in the group." The original report features Market Harmonic's 'Buy Rating' and 'Price Target of $5.00' on RHGP shares.

Tony Carrion, founder of Market Harmonics said in his report, "Renhuang's revenues compare favorably to some of its larger Chinese competitors, and the company has maintained average profit margins of 40% since 2005. When considering its performance relative to that of its peers and sector, we find the current valuation of the company's stock to be compelling, and affirm our preliminary 12-month target of $5.00."

"Assuming a P/E of 20.0X to represent the threshold between 'fair valuation' and 'overvaluation,' most of the issues in our CHSI Index are trading at a premium to their earnings. 25% of index of index constituents are trading below this threshold. On a valuation basis, Renhuang Pharmaceuticals displays the lowest P/E multiple of the group and performs well across the range of valuation multiples."

"Taking into account the stronger seasonality, continued improved cost efficiencies and the ability to bring more production online, we think it not unreasonable for Renhuang to have a slightly stronger finish for FY 2007 as it begins to take advantage of stepped-up production going into the end of the fiscal year (October 31)," reported Tony Carrion.

About Renhuang Pharmaceuticals, Inc.

Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP) is a leading integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products in the People's Republic of China.

Safe Harbor Statement

This press release contains certain statements that may include 'forward-looking statements' as defined in the Securities Act of 1933, and the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein are 'forward-looking statements.' Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with and available from the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

All material herein was prepared by CRG Partners, Inc. (CRGP) based upon information believed to be reliable. The information contained herein is not guaranteed by CRGP to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRGP is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. CRGP has been compensated by third party shareholders with shares or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRGP has been compensated twenty thousand shares for RHGP, and may receive an additional twenty thousand shares in future installments. CRGP may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRGP and its web site are operated under a license from Capital Research Group, Inc., Inc. and One Source Solutions Inc. (Licensors) and CRGP is not the agent of any of the Licensors and CRGP is solely responsible for all statements made herein. CRGP's affiliates, officers, directors and employees intend to buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. CRGP will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Contact: Joe Farrar President, CRG Partners, Inc. 973-332-1366